Health Care [ 8/12 ] | Pharmaceuticals [ 50/74 ]
NASDAQ | Common Stock
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.
It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease.
In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease.
It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets.
The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021.
Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 14, 26 | -0.19 Increased by +61.22% | -0.74 Increased by +74.32% |
| Mar 26, 26 | -0.24 Increased by +62.50% | -0.72 Increased by +66.67% |
| Nov 10, 25 | 0.18 Increased by +103.90% | -0.65 Increased by +127.69% |
| Aug 11, 25 | -0.56 Increased by +95.61% | -0.63 Increased by +11.11% |
| May 15, 25 | -0.49 | -0.54 Increased by +9.26% |
| Mar 27, 25 | -0.64 | -0.69 Increased by +6.80% |
| Nov 20, 24 | -4.62 | - |
| Aug 28, 24 | -12.76 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 26.52 M Increased by +12.01 K% | -8.64 M Increased by +59.78% | Decreased by -32.56% Increased by +99.67% |
| Dec 31, 25 | 24.12 M Increased by +11.28 K% | -10.74 M Increased by +48.05% | Decreased by -44.52% Increased by +99.54% |
| Sep 30, 25 | 21.50 M Increased by +12.11 K% | 8.17 M Increased by +139.82% | Increased by +38.02% Increased by +100.33% |
| Jun 30, 25 | 119.00 K Decreased by -67.84% | -24.84 M Decreased by -51.07% | Decreased by -20.87 K% Decreased by -369.72% |
| Mar 31, 25 | 219.00 K Decreased by -30.91% | -21.48 M Decreased by -51.60% | Decreased by -9.81 K% Decreased by -119.44% |
| Dec 31, 24 | 212.00 K Increased by +79.66% | -20.67 M Decreased by -159.23% | Decreased by -9.75 K% Decreased by -132.97% |
| Sep 30, 24 | 176.00 K Increased by +433.33% | -20.52 M Decreased by -87.51% | Decreased by -11.66 K% Increased by +64.84% |
| Jun 30, 24 | 370.00 K - | -16.44 M - | Decreased by -4.44 K% - |